Metformin plus sorafenib highly impacts temozolomide-resistant glioblastoma stem-like cells

Journal of B.U.ON.

Volumn 19, Issue 2, 2014, Pages 502-511

  Aldea, Mihaela D ^a   Petrushev, Bobe ^a   Soritau, Olga ^b   Tomuleasa, Ciprian I ^a   Berindan Neagoe, Ioana ^a   Filip, Adriana G ^a   Chereches, Gabriela ^b   Cenariu, Mihai ^c   Craciun, Lucian ^a   Tatomir, Corina ^b   Florian, Ioan Stefan ^a   Crivii, Carmen B ^a   Kacso, Gabriel ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Ion Chiricuta Comprehensive Cancer Center   (Romania)

^c UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

Author keywords

Glioblastoma; Metformin; Sorafenib; Stem like cells; Temozolomide

Indexed keywords

DICHLOROFLUORESCEIN; LIPOCORTIN 5; MALONALDEHYDE; METFORMIN; PRODIUM IODIDE; REACTIVE OXYGEN METABOLITE; REAGENT; RHODAMINE 123; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOBLASTOMA STEM CELL; HUMAN; HUMAN CELL; MONOTHERAPY; MTT ASSAY; OSTEOBLAST; STEM CELL; STEM CELL CULTURE; TREATMENT RESPONSE; TUMOR CELL CULTURE;

APOPTOSIS; BRAIN NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; LIPID PEROXIDATION; METFORMIN; NEOPLASTIC STEM CELLS; NIACINAMIDE; OXIDATIVE STRESS; PHENYLUREA COMPOUNDS; RAF KINASES; RHODAMINE 123; TOR SERINE-THREONINE KINASES;

EID: 84904200125     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Wen PY, Kesari S. Malignant gliomas in adults. NEJM 2008;359:492-507.
2. Niyazi M, Siefert A, Schwarz SB et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol 2011;98:1-14
3. Stupp R, Mason WR van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 2005;352:987-996.
4. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
5. Dimov I, Tasic-Dimov D, Conic I, Stefanovic V. Glioblastoma multiforme stem cells. Sci World J 2011;11:930-958.
6. Chamberlain MC. Temozolomide therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 2010;10:1537-1544
7. Tomuleasa C, Soritau O, Rus-Ciuca D et al. Functional and molecular characterization of glioblastoma multiforme-derived cancer stem cells. JBUON 2010;15.583-591.
8. Nakai E, Park K, Yawata T et al. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma Cancer Invest 2009;27:901-908.
9. Pistollato F, Abbadi S, Rampazzo E et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010;28:851-862.
10. Schlegel J, Merdes A, Stumm G et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 199456;72-77.
11. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 2002; 62:6764-6769. (Pubitemid 35364149)
12. Xu C, Wu X, Zhu J. VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2 Sci World J 2013;2013:413-417.
13. Kim Y, Kim E, Wu Q et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Develop 2012;26:1247-1262
14. Soroceanu L, Kharbanda S, Chen R et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sciences USA 2007;104:3466-3471. (Pubitemid 46364182)
15. Puputti M, Tynninen O, Sihto H et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 2006:4:927-934 (Pubitemid 46121551)
16. Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL Akt signaling is required for glioblastoma maintenance in vivo. Am J Cancer Res 2011;1:155-167.
17. Soritau O, Tomuleasa C, Aldea M. et al. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. JBUON 2011; 16:282-289.
18. Sato A, Sunayama J, Okada M, et al. Glioma-initiating cell elimination by metformin activation of FOX03 via AMPK. Stem Cells Transl Med 2012;1:811-824
19. Wurth R, Pattarozzi A, Gatti M et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 2013;12:145-156.
20. Ferla R, Haspinger E, Surmacz E. Metformin inhibits leptin-induced growth and migration of glioblastoma cells. Oncology Lett 2012;4:1077-1081.
21. Dowling RJ, Zakikhani M, Fantus IG, Poliak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-10812 (Pubitemid 350145909)
22. Gomez-Pinillos A, Ferrari AC. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 2012;26:483-505.
23. Carra E, Barbieri F, Marubbi D et al. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cyde 2013;12:491-500.
24. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109. (Pubitemid 39331023)
25. Tomuleasa CI, Foris V, Soritau O et al. Effects of 60Co gamma-rays on human osteoprogenitor cells. Roman J Morphol Embryol 2009;50:349-355.
26. Conti M, Morand PC, Levillain P, Lemonnier A. Improved fluorometric determination of malonaldehyde. Clin Chem 1991;37:1273-1275. (Pubitemid 21925960)
27. Lee JS, Pauli K, Alvarez M et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994;46:627-638. (Pubitemid 24334752)
28. Orza A, Soritau O, Tomuleasa C et al. Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomed 2013;8:689-702
29. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Mol Cancer 2006; 5:67.
30. Fouse SD, Nakamura JL, James CD, Chang S, Costello JF. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. Neurooncology 2014; 16:361-371.
31. Ropolo M, Daga A, Griffero F et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 2009;7:383-392
32. Gao Q, Lei T, Ye F. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma. Expert Opin Investig Drugs 2013;22:1023-1040.
33. Cheng CK, Fan QW, Weiss WA. PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathol 2009;19:112-120.
34. Peereboom DM, Ahluwalia MS, Ye X et al. NABTT 0502 a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neurooncology 2013;15:490-496.
35. Hainsworth JD, Ervin T, Friedman E et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010;116:3663-3669.
36. Hegi ME, Diserens AC, Bady P et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a phase II trial. Mol Cancer Ther 2011;10:1102-1112
37. Polivka J, Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2013; pii: S0163-7258 (13): 00240-4
38. Haugaard N. Cellular mechanisms of oxygen toxicity. Physiol Rev 1968;48:311-373.
39. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res 2000;4:410-418. (Pubitemid 30646063)
40. Isakovic A, Harhaji L, Stevanovic D et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007;64:1290-1302 (Pubitemid 46791062)
41. Mirmiranpour H, Mousavizadeh M, Noshad S et al. Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients a randomized clinical trial. J Diabetes Complic 2013;27:501-507.
42. Riganti C, Salaroglio IC, Caldera V et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/beta-catenin pathway. Neurooncology 2013;15:1502-1517.
43. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol 2010;202:383 e1-7.
44. Kim HG, Hien TT, Han EH et al. Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 2011;162:1096-1108.
45. Eum KH, Ahn SX Kang H, Lee M. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. Mol Cell Biochem 2013:372:65-74
46. Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharm Rep 2010; 62: 956-965.